US Patent

US9539258 — Quinazoline derivatives for the treatment of cancer diseases

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2026-11-09 · 0y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of quinazoline derivatives, specifically those of formula (I), in cancer therapy.

USPTO Abstract

The present invention relates to the use of quinazolines of formula (I), wherein the groups R a to R d have the meanings given in the claims and specification, in cancer therapy.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1950 — afatinib-dimaleate
U-1950 — afatinib-dimaleate
U-1950 — afatinib-dimaleate

Patent Metadata

Patent number
US9539258
Jurisdiction
US
Classification
Method of Use
Expires
2026-11-09
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.